Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 16 2026

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release regarding an agreement between Sentynl Therapeutics and PRG S&T to license a molecule for Hutchinson-Gilford Progeria Syndrome. The agreement allows Sentynl to acquire full rights to the investigational drug candidate Progerinin, which is intended for the treatment of this rare genetic disorder. This licensing deal is part of Sentynl's strategy to expand its portfolio of therapies for rare diseases, specifically targeting progeria. The press release emphasizes the importance of advancing treatments for patients affected by this severe condition.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Sentynl Therapeutics Enters into Agreement with PRG S&T to License Molecule for Hutchinson-Gilford Progeria Syndrome".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases